Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

In recent years, we have seen the development and approval for clinical use of an increasing number of therapeutic agents against actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC). Among them, selective inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Spagnolo, Calogera Claudia, Ciappina, Giuliana, Giovannetti, Elisa, Squeri, Andrea, Granata, Barbara, Lazzari, Chiara, Pretelli, Giulia, Pasello, Giulia, Santarpia, Mariacarmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299133/
https://www.ncbi.nlm.nih.gov/pubmed/37373267
http://dx.doi.org/10.3390/ijms241210119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299133/
https://www.ncbi.nlm.nih.gov/pubmed/37373267
http://dx.doi.org/10.3390/ijms241210119

Ejemplares similares